PHOENIX, May 22, 2024 /PRNewswire/ -- SenesTech, Inc. (Nasdaq: SNES; "SenesTech" or the "Company"), the leader in fertility control to manage animal pest populations, today announced that it has taken a significant step forward in the distribution of EvolveTM, the Company's minimum risk soft bait for the proactive control of rats, through the launch of a dedicated online store on Amazon, the world's largest online retailer. To purchase Evolve on Amazon, please visit this link. "Evolve isn't just a product; ...

财务数据和关键指标变化 - 公司在第一季度实现了创纪录的415,000美元收入,同比增长78% [9] - 收入增长主要得益于Evolve产品,占第一季度销售额的50%以上 [34] - 毛利率受到原材料成本上升的影响,但在第一季度末已得到纠正,4月份毛利率达到58% [37][38] - 经营费用同比下降8%,公司致力于进一步削减100万美元的年度经营费用 [39] - 净亏损同比改善20万美元,调整后EBITDA亏损为170万美元,为公司历史最小 [40] - 季末现金余额360万美元,未行使的短期认股权证可能成为未来现金来源 [41] 各条业务线数据和关键指标变化 - Evolve产品销售占比超过50%,成为公司主要收入来源 [34] - 专业害虫管理和商业客户渠道销售大幅增长 [34] - 公司已扩大Evolve产品的包装规格,从6磅和12磅桶装扩展到1.5磅和3磅袋装,以满足消费者市场需求 [18] 各个市场数据和关键指标变化 - 美国鼠类和害虫管理产品市场年销售额超过10亿美元,其中一半以上针对老鼠 [16] - 加州等地监管机构对常用毒药的使用施加更多限制,消费者和害虫管理人员正寻求新的控制方法 [16] 公司战略和发展方向及行业竞争 - 公司已建立6大销售渠道:电商、国际、农业、害虫管理、工业和零售 [17] - 在电商渠道,公司已在亚马逊开设专门店铺 [18] - 在国际渠道,公司已签署6个独家分销协议,覆盖香港、澳大利亚和阿联酋等市场 [19] - 在农业渠道,公司与Wilco Distributing、Poppe Enterprises和Agricom等公司达成合作 [20] - 在害虫管理渠道,公司与Tusera和DIY Pest Control等公司签约 [21][22] - 在工业渠道,公司正与一家拥有28名外部销售人员的代理商达成协议 [23] - 在零售渠道,公司已完成与一家拥有4,500家门店的全国性五金零售商的合作 [24][25] - 公司产品ContraPest和Evolve通过从根本上控制鼠类繁衍来解决鼠害问题,与传统的毒药和捕鼠器不同 [30][31] 管理层对经营环境和未来前景的评论 - Evolve产品在30个州获得批准,其余州份正在进行必要的功效研究,有望进一步加快增长 [10] - Evolve产品在亚利桑那大学的功效研究结果显示,一个繁衍周期内可减少61%的产仔量,6个月内可减少85%的种群,1年内可减少90%以上 [11][12] - Evolve Mouse产品的推出将使公司的目标市场翻倍 [14][16] - 公司有信心Evolve将成为鼠害控制的首选产品 [13] - 公司正在积极拓展各销售渠道,有望在2024年带来重要的销售增长 [26] 问答环节重要的提问和回答 问题1 **Ellie Jiang 提问** 预计Evolve Mouse产品在未来一个季度的销售情况如何? [45] **Jiazhen Zhao 回答** Evolve Mouse产品在不同州获批的进度可能会有所不同,但预计在今年内Evolve Mouse将占Evolve总销售的15%-25%左右 [46] 问题2 **Yang Bai 提问** 亚马逊商城的开设是否会影响公司自有网站的销售? [47] **Jiazhen Zhao 回答** 公司网站已有一些忠实客户,亚马逊渠道可能会吸引更多偏好该渠道的客户,但公司的定价策略是中性的,两个渠道并存不会产生明显的替代效应 [48] 问题3 **Joyce Ju 提问** 与主要害虫控制公司达成分销协议需要具备哪些条件? [49] **Lei Chen 回答** 公司正在与主要害虫控制公司保持联系,随着Evolve产品在实际应用中的进一步验证,以及公司与服务这些公司的分销商的合作,有望未来达成相关的供应协议 [50]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-37941 SENESTECH, INC. (Exact name of registrant as specified in its charter) Delaware 20-2079805 (Stat ...

Exhibit 99.1 SenesTech Announces First Quarter 2024 Financial Results PHOENIX, Ariz., May 9, 2024. SenesTech, Inc. (NASDAQ: SNES, “SenesTech” or the “Company”), the leader in fertility control to manage animal pest populations and the only manufacturer of commercially available, EPA-registered Rat Birth Control® products today announced financial results for the first quarter of 2024. Recent Highlights • Record quarterly revenues during Q1 2024 of $415,000, an increase of 78% compared to Q1 2023. • Evolve™, ...

SenesTech, Inc. (NASDAQ:SNES) Q4 2023 Earnings Conference Call February 21, 2024 5:00 PM ET Company Participants Robert Blum - Lytham Partners, IR Joel Fruendt - CEO Tom Chesterman - CFO Conference Call Participants Amit Dayal - H.C. Wainwright Operator Good afternoon, and welcome to the SenesTech Reports Fourth Quarter and Fiscal Year 2023 Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded. I'd now like to turn the conference over to Robert Blum with Lytham ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37941 SENESTECH, INC. (Exact name of registrant as specified in its charter) Delaware 20-2079805 (State or other j ...

Exhibit 99.1 SenesTech Announces 2023 Financial Results YTD 2024 total revenue up more than 80% compared to YTD 2023 driven by orders for EvolveTM soft bait PHOENIX, Ariz., February 21, 2024. SenesTech, Inc. (NASDAQ: SNES, “SenesTech” or the “Company”), the rodent fertility control experts and inventors of the only EPA-registered contraceptive for male and female rats, ContraPest®, today announced 2023 financial results. “During 2023, we executed on a number of key initiatives that will be the foundation to ...

SenesTech, Inc. (NASDAQ:SNES) Q3 2023 Earnings Conference Call November 9, 2023 5:00 PM ET Company Participants Robert Blum - Lytham Partners, IR Joel Fruendt - Chief Executive Officer Tom Chesterman - Chief Financial Officer Conference Call Participants Operator Good afternoon. And welcome to the SenesTech Reports Third Quarter Fiscal Year 2023 Financial Results Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-37941 SENESTECH, INC. (Exact name of registrant as specified in its charter) Delaware 20-2079805 ( ...

SenesTech Managing Animal Populations Through Fertility Control NASDAQ: SNES May 2023 INVESTOR PRESENTATION SenesTech Disclaimer Special Note Regarding Forward Looking Statements ...